Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition

被引：5

作者：

Deak, Laura Codarri ^{[1
]}

Hashimoto, Masao ^{[2
,3
]}

Umana, Pablo ^{[1
]}

Klein, Christian ^{[1
]}

机构：

[1] Roche Pharm Res & Early Dev, Roche Innovat Ctr Zurich, Canc Immunotherapy Discovery, Roche Glycart AG Wagistr 10, CH-8952 Schlieren, Switzerland

[2] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA

[3] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA USA

来源：

ONCOIMMUNOLOGY | 2023年 / 12卷 / 01期

关键词：

Eciskafusp alfa; IL-2; PD-1; PD1-IL2v; RG6279; TCF-1; CYTOKINE;

D O I：

10.1080/2162402X.2023.2197360

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1(+) T-cells and acts on antigen-specific stem-like PD-1(+) TCF-1(+) CD8(+) T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.

引用

页数：3

共 25 条

[21] Dual checkpoint inhibition in M2 macrophages via anti-PD-L1 and siRNA-Loaded M1-Exosomes: Enhancing tumor immunity through RNA-targeting Strategies
Mahmoudi, Mohammad
Taghavi-Farahabadi, Mahsa
Hashemi, Seyed Mahmoud
Ghanbarian, Hossein
Noorbakhsh, Farshid
Mousavizadeh, Kazem
Mojtabavi, Nazanin
Rezaei, Nima
EUROPEAN JOURNAL OF PHARMACOLOGY, 2025, 990
[22] Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
Bernatchez, Chantale
Haymaker, Cara L.
Hurwitz, Michael E.
Kluger, Harriet M.
Tetzlaff, Michael T.
Jackson, Natalie
Gergel, Ivan
Tagliaferri, Mary Ann
Zalevsky, Jonathan
Hoch, Ute
Fanton, Christie
Iacucci, Ernesto
Aung, Sandra
Imperiale, Michael
Liao, Ej
Bentebibel, Salah E.
Tannir, Nizar M.
Hwu, Patrick
Sznol, Mario
Diab, Adi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[23] High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition
Tarhini, Ahmad A.
Eroglu, Zeynep
Galuia, Mariem
Eljilany, Islam
Kalos, Denise
Schell, Michael J.
Tetteh, Leticia
Abraham, Edith
Richards, Allison
Brohl, Andrew Scott
Khushalani, Nikhil I.
Markowitz, Joseph
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] INHIBITION OF THE SERINE THREONINE PROTEIN PHOSPHATASES PP1 AND PP2A IN LYMPHOCYTES - EFFECT ON MESSENGER-RNA LEVELS FOR INTERLEUKIN-2, IL-2R-ALPHA, KROX-24, P53, HSC70 AND CYCLOPHILIN
RICHARDS, FM
MILNER, J
METCALFE, S
IMMUNOLOGY, 1992, 76 (04) : 642 - 647
[25] A novel antibody-enabled dual precision targeted protein stabilization (TPS2) that augments anti-tumor immune response by targeting CBL-B inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
Lim, Joanne
Skaletskaya, Anna
Permpoon, Uttapol
Kim, Yeonjoon
Saini, Shikha
Takrouri, Khuloud
Ribkovskaia, Zinaida
Bhar, Palash
Fishkin, Nathan
Choi, Dong-Ki
Park, Ji Hyun
Palacino, James
Park, Peter U.
CANCER RESEARCH, 2023, 83 (07)

← 1 2 3 →